Photo from Nitin Jain/X
May 22, 2024, 01:53
Nitin Jain: Looking forward to presenting phase 2 trial of frontline treatment for patients with CLL at EHA 2024
Nitin Jain, Professor of the Department of Leukemia at MD Anderson Cancer Center, shared on X:
“Looking forward to presenting investigator initiated phase 2 trial of time-limited pirtobrutinib plus venetoclax plus obinutuzumab as frontline treatment for patients with CLL at EHA 2024.” .
Read further.
Source: Nitin Jain/X